ID
37674
Beskrivning
Study ID: 111592 Clinical Study ID: 111592 Study Title: A Randomized, Double-blind, Placebo-controlled, Doseescalation Study to Assess the Anti-inflammatory Activity, Efficacy, and Safety of Intravenous SB-681323 in Subjects at Risk for Development of Acute Lung Injury or ARDS Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00996840 See https://clinicaltrials.gov/ct2/show/NCT00996840 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Placebo, SB-681323 Trade Name: N/A Study Indication: Lung Injury, Acute The primary objective of this phase 2 trial is to evaluate the safety and tolerability of intravenous dilmapimod/SB-681323 given in escalating dosages and over different intervals for three days in trauma patients at risk for the development of ALI or ARDS. This study consists of Screening, infusion of dilmapimod/SB-681323 on days 1-3, examination/sampling up to early day 5 (denoted as "Day 3 - 48 hrs") and a Follow-up on day 7. There are four cohorts, cohorts 1 and 3 receive the medication (or placebo) infusion over 4 hours, cohorts 2 and 4 over 24 hours. This form is to be filled with data regarding pharmacodynamic results relating to the coagulation system and lung epithelial cell injury, taken repeatedly on Day 1 and 3, and can also be used for repeat analyses.
Länk
https://clinicaltrials.gov/ct2/show/NCT00996840
Nyckelord
Versioner (2)
- 2019-08-13 2019-08-13 -
- 2019-08-15 2019-08-15 - Sarah Riepenhausen
Rättsinnehavare
GlaxoSmithKline
Uppladdad den
15 augusti 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
SB-681323 in ALI/ARDS risk patients - NCT00996840
Pharmacodynamics Results
- StudyEvent: ODM
Beskrivning
Pharmacodynamics Results
Alias
- UMLS CUI-1
- C0851347
- UMLS CUI-2
- C1254595
Beskrivning
[read-only]
Datatyp
datetime
Alias
- UMLS CUI [1,1]
- C3897500
- UMLS CUI [1,2]
- C0304229
- UMLS CUI [1,3]
- C0178602
Beskrivning
Sample date/time
Datatyp
datetime
Alias
- UMLS CUI [1,1]
- C0200345
- UMLS CUI [1,2]
- C1264639
- UMLS CUI [1,3]
- C0031328
Beskrivning
INR Result Type
Datatyp
integer
Alias
- UMLS CUI [1,1]
- C0525032
- UMLS CUI [1,2]
- C1274040
- UMLS CUI [1,3]
- C0332307
Beskrivning
if applicable
Datatyp
float
Alias
- UMLS CUI [1,1]
- C2347373
- UMLS CUI [1,2]
- C0525032
Beskrivning
if applicable
Datatyp
text
Alias
- UMLS CUI [1,1]
- C1274040
- UMLS CUI [1,2]
- C2350015
- UMLS CUI [1,3]
- C0525032
Beskrivning
PT Result Type
Datatyp
integer
Alias
- UMLS CUI [1,1]
- C1274040
- UMLS CUI [1,2]
- C0332307
- UMLS CUI [1,3]
- C0491338
Beskrivning
if applicable
Datatyp
float
Alias
- UMLS CUI [1,1]
- C2347373
- UMLS CUI [1,2]
- C0491338
Beskrivning
if applicable
Datatyp
text
Alias
- UMLS CUI [1,1]
- C1274040
- UMLS CUI [1,2]
- C2350015
- UMLS CUI [1,3]
- C0491338
Beskrivning
PTT Result Type
Datatyp
integer
Alias
- UMLS CUI [1,1]
- C0030605
- UMLS CUI [1,2]
- C1274040
- UMLS CUI [1,3]
- C0332307
Beskrivning
if applicable
Datatyp
float
Alias
- UMLS CUI [1,1]
- C2347373
- UMLS CUI [1,2]
- C0030605
Beskrivning
if applicable
Datatyp
text
Alias
- UMLS CUI [1,1]
- C1274040
- UMLS CUI [1,2]
- C2350015
- UMLS CUI [1,3]
- C0030605
Similar models
Pharmacodynamics Results
- StudyEvent: ODM
C1254595 (UMLS CUI-2)
C0304229 (UMLS CUI [1,2])
C0178602 (UMLS CUI [1,3])
C1264639 (UMLS CUI [1,2])
C0031328 (UMLS CUI [1,3])
C1274040 (UMLS CUI [1,2])
C0332307 (UMLS CUI [1,3])
C0525032 (UMLS CUI [1,2])
C2350015 (UMLS CUI [1,2])
C0525032 (UMLS CUI [1,3])
C0332307 (UMLS CUI [1,2])
C0491338 (UMLS CUI [1,3])
C0491338 (UMLS CUI [1,2])
C2350015 (UMLS CUI [1,2])
C0491338 (UMLS CUI [1,3])
C1274040 (UMLS CUI [1,2])
C0332307 (UMLS CUI [1,3])
C0030605 (UMLS CUI [1,2])
C2350015 (UMLS CUI [1,2])
C0030605 (UMLS CUI [1,3])
Inga kommentarer